Media coverage about Celgene (NASDAQ:CELG) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celgene earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.494566738136 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Celgene (CELG) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- CELGENE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors … (businesswire.com)
- CELGENE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ce (markets.financialcontent.com)
- EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class … (businesswire.com)
- EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG (finance.yahoo.com)
CELG has been the topic of a number of research analyst reports. Sanford C. Bernstein cut Celgene from an “outperform” rating to a “market perform” rating and set a $121.00 price target on the stock. in a report on Wednesday, December 27th. SunTrust Banks restated a “buy” rating and set a $139.00 price target (up from $127.00) on shares of Celgene in a report on Friday, January 26th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price target on the stock in a report on Thursday, January 25th. Zacks Investment Research cut Celgene from a “hold” rating to a “sell” rating in a report on Tuesday, December 26th. Finally, Mizuho set a $128.00 price target on Celgene and gave the stock a “buy” rating in a report on Friday, January 5th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $126.95.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. Celgene’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.61 EPS. sell-side analysts predict that Celgene will post 7.69 EPS for the current fiscal year.
Celgene announced that its board has approved a share repurchase plan on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its stock is undervalued.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the sale, the director now directly owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark J. Alles purchased 3,260 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now directly owns 178,904 shares in the company, valued at approximately $16,441,277.60. The disclosure for this purchase can be found here. Insiders sold a total of 41,120 shares of company stock valued at $3,879,509 over the last three months. 0.95% of the stock is currently owned by insiders.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.